<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>RATIONALE: Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> is the second leading cause of <z:hpo ids='HP_0000726'>dementia</z:hpo>, which is strongly associated with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:hpo ids='HP_0000726'>dementia</z:hpo> have become a major public health concern worldwide </plain></SENT>
<SENT sid="2" pm="."><plain>At this point of time, it is very important to find the possible pharmacological agents which may be useful in management and therapy of <z:hpo ids='HP_0000726'>dementia</z:hpo> including <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, etc </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVES: To investigate the effect of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> on <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> (STZ) <z:mp ids='MP_0002055'>diabetes</z:mp> induced vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> in rats </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: <z:mp ids='MP_0002055'>Diabetes</z:mp> and subsequent <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and <z:hpo ids='HP_0000726'>dementia</z:hpo> were induced in rats by administration of single dose of STZ </plain></SENT>
<SENT sid="5" pm="."><plain>Drug treatment was started after 1Â month of STZ administration and treatment was continued until the end of the study </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0001465'>Morris water maze</z:mp> (MWM) test was employed for testing learning and memory </plain></SENT>
<SENT sid="7" pm="."><plain>Endothelial function was measured on isolated aortic rings using student physiograph </plain></SENT>
<SENT sid="8" pm="."><plain>Serum <z:chebi fb="105" ids="17234">glucose</z:chebi>, body weight, serum <z:chebi fb="95" ids="16301">nitrite</z:chebi>/nitrate, aortic <z:chebi fb="1" ids="18421">superoxide</z:chebi> <z:chebi fb="5" ids="22563">anion</z:chebi> generation, brain <z:chebi fb="0" ids="33202">thiobarbituric acid</z:chebi> reactive species (TBARS), reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> (GSH) levels, and acetylcholinesterase activity were also tested </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: STZ treatment produced <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, impairment of learning and memory, reduction in body weight and serum <z:chebi fb="95" ids="16301">nitrite</z:chebi>/nitrate, and increase in serum <z:chebi fb="105" ids="17234">glucose</z:chebi>, aortic and brain <z:mp ids='MP_0003674'>oxidative stress</z:mp> (increased <z:chebi fb="1" ids="18421">superoxide</z:chebi> <z:chebi fb="5" ids="22563">anion</z:chebi>, TBARS, and decreased GSH levels), and brain acetylcholinesterase activity </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> attenuated <z:mp ids='MP_0002055'>diabetes</z:mp> induced impairment of learning, memory, endothelial function, and various biochemical parameters </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="199" ids="26708">Sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> may be considered as potential pharmacological agent for the management of <z:mp ids='MP_0002055'>diabetes</z:mp> induced vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>